Related Experiment Videos
Common mechanisms in immune-mediated inflammatory disease
Gary S Firestein1, Maripat Corr
1Division of Rheumatology, Allergy, and Immunology, Department of Medicine, University of California at San Diego, San Diego, California, USA. gfirestein@ucsd.edu
The Journal of Rheumatology. Supplement
|February 5, 2005
Summary
The K/BxN mouse model revealed immune complex-mediated inflammation in rheumatoid arthritis (RA). Key factors like Fc receptors and complement drive arthritis, leading to targeted RA therapies.
Area of Science:
- Immunology
- Rheumatology
- Inflammation Research
Background:
- Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by joint inflammation.
- Immune complex-mediated inflammation plays a significant role in RA pathogenesis.
- The K/BxN mouse model offers a valuable platform for studying RA mechanisms.
Purpose of the Study:
- To characterize the K/BxN mouse model of spontaneous arthritis.
- To elucidate the role of immune complex-mediated inflammation in RA.
- To identify key molecular pathways and factors involved in RA development and perpetuation.
Main Methods:
- Induction of arthritis in K/BxN mice.
- Serum transfer experiments to normal recipient mice.
- Analysis of inflammatory mediators and cellular components involved in joint inflammation.
Main Results:
- The K/BxN mouse model recapitulates key features of human RA, including joint inflammation.
- Serum transfer from K/BxN mice induced joint-specific arthritis in normal mice.
- Fc receptors, interleukin 1, mast cells, and complement were identified as essential for serum transfer-induced arthritis.
- Cytokines, mitogen-activated protein kinases, and nuclear factor kappa B were implicated as amplifying factors in RA inflammation.
Conclusions:
- The K/BxN mouse model is instrumental in understanding immune complex-mediated inflammation in RA.
- Targeting specific inflammatory pathways identified in this model holds promise for RA treatment.
- Further research into these pathways can lead to improved clinical outcomes for RA patients.